Jul 7, 2023 07:39 PM
(This post was last modified: Jul 7, 2023 08:02 PM by C C.)
Anonymous: "The road to Hell is paved with good intentions" should be called the do-gooder fallacy. Since it seems to entail the belief that a noble act or an act supposedly motivated by noble intent will either magically work out or not make things worse simply because it is noble. Astonishing how the brains of the otherwise most secular, critically minded people will abruptly fall-out of if you sprinkle some "do-gooder" dust on a proposal, project, or ideology. It's as if the heavens opened up to divinely bless the initiative, with the freethinkers promptly falling on their knees and vowing to see the worthy goal to its fruition, following the unvetted method or dogma as prescribed.
- - - - - - -
https://www.statnews.com/2023/07/06/bide...-property/
INTRO (Stephen J. Ubl): When then-Vice President Biden launched the Cancer Moonshot in 2016, there was reason to be optimistic. Decades of rigorous science had transformed many cancers from a death sentence to a manageable chronic disease. New treatment advances — including gene and cell therapies and immunotherapies — were showing stunning results. With support from the biopharmaceutical industry and the help of smart government policies, ending cancer was, and is, an achievable goal.
Unfortunately, while the president promised a war on cancer, he declared a war on the cure instead. As the head of PhRMA, an association representing America’s leading biopharmaceutical research companies, I work with my team to closely follow the policy debate and the impact on innovation. While they may have been well-intended, the Biden administration has adopted a series of policies that attack critical steps needed to bring new treatments out of the lab and to the patients who need them.
First, the administration eroded the foundation of scientific innovation by subverting intellectual property protections. In 2022, the White House caved to foreign competitors and global activists by agreeing at the World Trade Organization ministerial conference to waive IP protections that enabled the development of Covid-19 vaccines.
That caused the first tear in the IP fabric, signaling the United States would no longer vigorously defend the IP rights of researchers. Countries including China and India are now angling to waive IP protections for Covid-19 treatments, including those that could potentially treat cancer and other diseases. The administration has been unwilling to stop this global IP heist.
For life sciences companies, IP is the foundation. The certainty of knowing it will have exclusive rights for a limited time before copies hit the market is what enables companies to make long-term, risky investments into new medicines.
Next, the administration signed legislation giving them the authority to unilaterally determine the value of innovative medicines. Under the guise of “negotiation,” the Inflation Reduction Act (IRA) allows the federal government to set the price of medicines in Medicare.
Every time it has been tried around the world, government price setting reduces patient access to new cures and treatments... (MORE - details)
- - - - - - -
https://www.statnews.com/2023/07/06/bide...-property/
INTRO (Stephen J. Ubl): When then-Vice President Biden launched the Cancer Moonshot in 2016, there was reason to be optimistic. Decades of rigorous science had transformed many cancers from a death sentence to a manageable chronic disease. New treatment advances — including gene and cell therapies and immunotherapies — were showing stunning results. With support from the biopharmaceutical industry and the help of smart government policies, ending cancer was, and is, an achievable goal.
Unfortunately, while the president promised a war on cancer, he declared a war on the cure instead. As the head of PhRMA, an association representing America’s leading biopharmaceutical research companies, I work with my team to closely follow the policy debate and the impact on innovation. While they may have been well-intended, the Biden administration has adopted a series of policies that attack critical steps needed to bring new treatments out of the lab and to the patients who need them.
First, the administration eroded the foundation of scientific innovation by subverting intellectual property protections. In 2022, the White House caved to foreign competitors and global activists by agreeing at the World Trade Organization ministerial conference to waive IP protections that enabled the development of Covid-19 vaccines.
That caused the first tear in the IP fabric, signaling the United States would no longer vigorously defend the IP rights of researchers. Countries including China and India are now angling to waive IP protections for Covid-19 treatments, including those that could potentially treat cancer and other diseases. The administration has been unwilling to stop this global IP heist.
For life sciences companies, IP is the foundation. The certainty of knowing it will have exclusive rights for a limited time before copies hit the market is what enables companies to make long-term, risky investments into new medicines.
Next, the administration signed legislation giving them the authority to unilaterally determine the value of innovative medicines. Under the guise of “negotiation,” the Inflation Reduction Act (IRA) allows the federal government to set the price of medicines in Medicare.
Every time it has been tried around the world, government price setting reduces patient access to new cures and treatments... (MORE - details)